[ad_1]
The FDA has explained that Larotrectinib Vitrakvi, approved by the US Food and Drug Administration (FDA), serves a specific segment of cancer patients, but not all.
The drug, larotrectinib (Vitrakvi), acts innovatively by preventing the growth of tumors caused by a rare genetic defect (genetic mutation), causing some cases of cancer, allowing the drug to be treated and treated. A specific segment of patients, not all patients with cancer.
The drug has received accelerated accreditation from the FDA, a measure adopted by the WHO for drugs that work in innovative ways or that could form the nucleus of a promising therapeutic future.
The results of studies that led to its efficacy were noted and the drug was adopted, indicating that studies were conducted on 55 patients, including 12 patients under 18 years of age with rare genetic mutation (NTRK). The answer was good. Number of patients who have experienced the most common symptoms, such as fatigue, nausea, vomiting, elevated liver enzymes, dizziness, diarrhea and constipation.
The SFDA said that options and treatment methods for cancer patients were growing. They will be available once they have been subjected to studies on safety and security, confirming that they are following scientific developments related to drugs or therapeutic methods and seeking to provide the patient with drugs and medicines. safe and effective treatment methods.
[ad_2]
Source link
